Atacand

ApprovedSmall molecule

AstraZeneca

Atacand is one of 84 small molecule programs targeting Mitral regurgitation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

Congestive Heart FailureActive, not recruiting

HypertensionActive, not recruiting

Mitral RegurgitationApproved

Active, not recruiting

Congestive Heart FailureApproved

Active, not recruiting

HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Atacand

AstraZeneca

Approved

2 2

Edarbi

Takeda

Preclinical

10 3

Apresoline

Novartis

Preclinical

7 4

Benicar

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Winrevair

Merck & Co.

Preclinical

—8

Disalcid

JJoslin Diabetes Center

Preclinical

1 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension2 trials

The Precision Hypertension Care Study

Completed·UUppsala University·Phase 4·NCT02774460·280 enrolled

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00227318·1,000 enrolled

Mitral regurgitation1 trial

Angiotensin-II Blockade in Mitral Regurgitation

Completed·MMayo Clinic·Phase 4·NCT00587470·60 enrolled

Fasting Conditions1 trial

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Completed· GSK logo

GSK·Phase 1·NCT02254447·18 enrolled

Congestive Heart Failure1 trial

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT01682564·169 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Atacand. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atacand compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atacand. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Atacand

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension2 trials

Mitral regurgitation1 trial

Fasting Conditions1 trial

Congestive Heart Failure1 trial

References

Drug Info

Quick Facts

Related News